Quality of life in patients with advanced ovarian cancer after primary debulking surgery versus neoadjuvant chemotherapy: results from the randomised SCORPION trial (NCT01461850).

We found no difference in global QoL related to treatment approach at 12 months, even though patients in the NACT/IDS group reported better global health scores across the 12-month period compared with the PDS group; these findings further confirm that NACT/IDS might be a feasible option for patients unsuitable for PDS.